(News Bulletin 247) – Invest Securities maintains its buy rating on the Biomérieux share, with a price target reduced from 122 to 118 euros, after the company announced 2022 results without surprise.
“The strong growth of non-RP panels, the continued expansion of the installed base, the rebound in immunoassays are all positive signals in the short term”, underlines the analysis office, which further specifies that the 2023 objectives have been reiterated.
“The market hides many levers that have not yet been delivered and that will allow the group to effectively digest the post-Covid period. Biomérieux also has sufficient resources to make new acquisitions to consolidate its medium-term prospects,’ concludes the analyst.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
_103917.jpg?fit=%2C&ssl=1)
